The U.S. market for diabetes diagnosis, treatment and drug delivery is expected to exceed $17.87 billion by 2018.
The market segments covered in this report include:
Market growth is expected to be fueled by an increasing number of diabetics and improved education regarding the importance of blood glucose management. Factors such as high obesity rates, poor diet and lack of exercise will contribute to the growing type 2 diabetic population.
Market growth for diabetes diagnosis, treatment and drug delivery will be led by double-digit growth in the continuous glucose monitor, insulin pen and insulin pump segments.
Within the diabetes diagnosis, treatment and drug deliver market, companies such as Novo Nordisk, Sanofi, Eli Lilly and Lifescan lead the market, among many others. This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2018, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.